Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorGomez Lara, Josep
dc.contributor.authorOyarzabal, Loreto
dc.contributor.authorOrtega-Paz, Luis
dc.contributor.authorBrugaletta, Salvatore
dc.contributor.authorRomaguera, Rafael
dc.contributor.authorSalvatella, Neus
dc.contributor.authorOtaegui Irurueta, Imanol
dc.date.accessioned2022-05-31T07:18:53Z
dc.date.available2022-05-31T07:18:53Z
dc.date.issued2021-11-16
dc.identifier.citationGomez-Lara J, Oyarzabal L, Ortega-Paz L, Brugaletta S, Romaguera R, Salvatella N, et al. Coronary Endothelium-Dependent Vasomotor Function After Drug-Eluting Stent and Bioresorbable Scaffold Implantation. J Am Heart Assoc. 2021 Nov 16;10(22):e022123.
dc.identifier.issn2047-9980
dc.identifier.urihttps://hdl.handle.net/11351/7590
dc.descriptionMyocardial infarction; Endothelial dysfunction; Optical coherence tomography
dc.description.abstractBackground Early generation drug‐eluting stents (DESs) showed a high grade of coronary endothelial dysfunction that was attributed to lack of stent reendothelialization. Endothelium‐dependent vasomotor response of current DESs and bioresorbable scaffolds (BRSs) remains unknown. This study sought to assess the device‐related endothelial function of current devices and to correlate neointima healing with endothelial function. Methods and Results A total of 206 patients from 4 randomized trials treated with the durable‐polymer everolimus‐eluting Xience (n=44), bioresorbable‐polymer sirolimus‐eluting Orsiro (n=35), polymer‐free biolimus‐eluting Biofreedom (n=24), bioactive endothelial‐progenitor cell‐capturing sirolimus‐eluting Combo DES (n=25), polymer‐based everolimus‐eluting Absorb (n=44), and Mg‐based sirolimus‐eluting Magmaris BRS (n=34) underwent endothelium‐dependent vasomotor tests and optical coherence tomography imaging, as per protocol, at follow‐up. Crude vasomotor responses of distal segments to low‐dose acetylcholine (10−6 mol/L) were different between groups: bioresorbablepolymer DEShad the worst (−8.4%±12.6%) and durable‐polymer DES had the most physiologic (−0.4%±11.8%; P=0.014). High‐dose acetylcholine (10−4 mol/L) showed similar responses between groups (ranging from −10.8%±11.6% to −18.1%±15.4%; P=0.229). Device healing was different between devices. Uncovered struts ranged from 6.3%±7.1% (bioresorbable‐polymer DES) to 2.5%±4.5% (bioactive DES; P=0.056). In multivariate models, endothelium‐dependent vasomotor response was associated with age, bioresorbable‐polymer DES, and angiographic lumen loss, but not with strut coverage nor plaque type. Endothelial dysfunction (defined as ≥4% vasoconstriction) was observed in 46.6% of patients with low‐dose and 68.9% with high‐dose acetylcholine, without differences between groups. Conclusions At follow‐up, endothelial dysfunction was frequently observed in distal segments treated with current stents without remarkable differences between devices. Although neointima healing was different between devices, poor healing was not associated with endothelial dysfunction.
dc.language.isoeng
dc.publisherWiley
dc.relation.ispartofseriesJournal of the American Heart Association;10(22)
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScientia
dc.subjectCor - Malalties - Tractament
dc.subjectMedicaments - Alliberament retardat
dc.subjectCor - Malalties - Cirurgia
dc.subject.meshPercutaneous Coronary Intervention
dc.subject.meshDrug-Eluting Stents
dc.subject.meshCoronary Disease
dc.titleCoronary Endothelium‐Dependent Vasomotor Function After Drug‐Eluting Stent and Bioresorbable Scaffold Implantation
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1161/JAHA.121.022123
dc.subject.decscirugía coronaria percutánea
dc.subject.decsstents liberadores de fármacos
dc.subject.decsenfermedad coronaria
dc.relation.publishversionhttps://doi.org/10.1161/JAHA.121.022123
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Gomez-Lara J, Romaguera R] University Hospital of Bellvitge, Biomedical Resarch Institute of Bellvitge (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Spain. [Oyarzabal L] University Hospital of Bellvitge, Biomedical Resarch Institute of Bellvitge (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Spain. Clinic Hospital of Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. [Ortega-Paz L, Brugaletta S] Clinic Hospital of Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. [Salvatella N] Heart Disease Reseacrh Group, Mar Hospital, Biomedical Research Institute of Mar Hospital (IMIM), Barcelona, Spain. [Otaegui I] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid34729992
dc.identifier.wos000718875100023
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record